FDA issued a draft guidance for Drugs and Biologics titled: Data Integrity and Compliance With CGMP. While s number of the concepts are conceptually relevant to device manufacturers one must be careful with interpretation since the requirements in this guidance are specifically related to elements of the Drug CGMPs and these are not identical to the requirements of Device CGMPs in 21 CFR 820 and related regualtions.